
NASDAQIndustrialsSpecialty Business Services
最新数据
US$1.95
+US$0.05 · +2.63%
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
前收盘价
US$1.95
+US$0.05 · +2.63%
盘中时间采用ET。市场数据可能有所延迟。
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
日内区间
当前US$1.95
52周区间
当前US$1.95
盘中时间采用ET。市场数据可能有所延迟。
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
日内区间
当前US$1.95
52周区间
当前US$1.95
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。